Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in IBD Patients With Active Skin Extra-intestinal Manifestations
NCT03139032Phase 2Terminated
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Jul 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of etrasimod in inflammatory bowel disease (IBD), pyoderma gangrenosum (PG), erythema nodosum, psoriasis, sponsored by Arena Pharmaceuticals, Inc.. Started Jul 2017; status: terminated.
02
Drugs
etrasimod
03
Conditions
inflammatory bowel disease (IBD)pyoderma gangrenosum (PG)erythema nodosumpsoriasis
Beyond the preview
Go deeper on NCT03139032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03139032.